Factors that influence VSV-G pseudotyping and transduction efficiency of lentiviral vectors - In vitro and in vivo implications

Journal of Gene Medicine

Volumn 9, Issue 5, 2007, Pages 345-356

  Farley, Daniel C ^a   Iqball, Sharifah ^a   Smith, Joanne C ^a   Miskin, James E ^a   Kingsman, Susan M ^a   Mitrophanous, Kyriacos A ^a  

^a Oxford BioMedica UK Ltd   (United Kingdom)

Author keywords

Glycosylation; Pseudotyping; Restriction; Titre; Vector; VSV G

Indexed keywords

LENTIVIRUS VECTOR; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ARTICLE; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; GENETIC TRANSDUCTION; HOST CELL; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PSEUDOTYPING; QUANTITATIVE ANALYSIS; SPECIES DIFFERENCE; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS TITRATION;

ANIMALS; CELL LINE; GENETIC VECTORS; GLYCOSYLATION; HUMANS; LENTIVIRUS; MEMBRANE GLYCOPROTEINS; PROTEIN ISOFORMS; SPECIES SPECIFICITY; TRANSDUCTION, GENETIC; VESICULAR STOMATITIS-INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRION;

MAMMALIA; PRIMATES; VESICULAR STOMATITIS VIRUS;

EID: 34249026485     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1022     Document Type: Article

References (73)

1. Zadava J. The pseudotype paradox. J Gen Virol 1982; 63: 15-24.
2. Brown EL, Lyles DS. Pseudotypes of vesicular stomatitis virus with CD4 formed by clustering of membrane microdomains during budding. J Virol 2005; 79: 7077-7086.
3. Burns JC, Friedmann T, Driever W, et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nomnammalian cells. Proc Natl Acad Sci U S A 1993; 90: 8033-8037.
4. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005; 5: 387-398.
5. Galipeau J, Li H, Paquin A, et al. Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Res 1999; 59: 2384-2394.
6. Wong LF, Azzouz M, Walmsley LE, et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther 2004; 9: 101-111.
7. Rovira A, De Angioletti M, Camacho-Vanegas O, et al. Stable invivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. Blood 2000; 96: 4111-4117.
8. Auricchio A, Kobinger G, Anand V, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 2001; 10: 3075-3081.
9. Shi PA, De Angioletti M, Donahue RE, et al. In vivo gene marking of rhesus macaque long-term repopulating hematopoietic cells using a VSV-G pseudotyped versus amphotropic oncoretroviral vector. J Gene Med 2004; 6: 367-373.
10. Tarantal AF, O'Rourke JP, Case SS, et al. Rhesus monkey model for fetal gene transfer: studies with retroviral-based vector systems. Mol Ther 2001; 3: 128-138.
11. Whitelaw CB, Radcliffe PA, Ritchie WA, et al. Efficient generation oi transgenic pigs using equine infectious anaemia virus (EIAV) derived vector. FEBS Lett 2004; 571: 233-236.
12. McGrew MJ, Sherman A, Ellard FM, et al. Efficient production of germline transgenic chickens using lentiviral vectors. EMBO Rep 2004; 5: 728-733.
13. Zhou X, Cui Y, Huang X, et al. Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther 2003; 14: 1089-1105.
14. Ikeda Y, Collins MK, Radcliffe PA, et al. Gene transduction efficiency in cells of different species by HIV and EIAV vectors. Gene Ther 2002; 9: 932-938.
15. Schlegel R, Tralka TS, Willingham MC, et al. Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell 1983; 32: 639-646.
16. Seganti L, Superti F, Girmenia C, et al. Study of receptors for vesicular stomatitis virus in vertebrate and invertebrate cells. Microbiologica 1986; 9: 259-267.
17. Viti D, Sinibaldi L, Superti F, et al. VSV binding to lipids from different cell lines. Brief report. Arch Virol 1987; 93: 279-285.
18. Carneiro FA, Bianconi ML, Weissmuller G, et al. Membrane recognition by vesicular stomatitis virus involves enthalpy-driven protein-lipid interactions. J Virol 2002; 76: 3756-3764.
19. Schlegel R, Willingham MC, Pastan IH. Saturable binding sites for vesicular stomatitis virus on the surface of Vero cells. J Virol 1982; 43: 871-875.
20. Coil DA, Miller AD. Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol 2004; 78: 10920-10926.
21. Coil DA, Miller AD. Enhancement of enveloped virus entry by phosphatidylserine. J Virol 2005; 79: 11496-11500.
22. Molinari M. Folding of viral glycoproteins in the endoplasmic reticulum. Virus Res 2002; 82: 83-86.
23. Hammond C, Helenius A. Quality control in the secretory pathway: retention of a misfolded viral membrane glycoprotein involves cycling between the ER, intermediate compartment, and Golgi apparatus. J Cell Biol 1994; 126: 41-52.
24. Machamer CE, Florkiewicz RZ, Rose JK. A single N-linked oligosaccharide at either of the two normal sites is sufficient for transport of vesicular stomatitis virus G protein to the cell surface. Mol Cell Biol 1985; 5: 3074-3083.
25. Kotwal GJ, Buller ML, Wunner WH, et al. Role of glycosylation. in transport of vesicular stomatitis virus envelope glycoprotein. A new class of mutant defective in glycosylation and transport of G protein. J Biol Chem 1986; 261: 8936-8943.
26. Lee K, KewalRamani VN. In defense of the cell: TRIM5alpha interception of mammalian retroviruses. Proc Natl Acad Sci U S A 2004; 101: 10496-10497.
27. Goff SP. Retrovirus restriction factors. Mol Cell 2004; 16: 849-859.
28. Bieniasz PD. Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 2004; 5: 1109-1115.
29. Towers GJ. Control of viral infectivity by tripartite motif proteins. Hum Gene Ther 2005; 16: 1125-1132.
30. Mangeat B, Trono D. Lentiviral vectors and antiretroviral intrinsic immunity. Hum Gene Ther 2005; 16: 913-920.
31. Yap MW, Nisole S, Lynch C, et al. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 2004; 101: 10786-10791.
32. Schmitz C, Marchant D, Neil SJ, et al. Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J Virol 2004;78: 2006-2016.
33. Reuter S, Kaumanns P, Buschhorn SB, et al. Role of HIV-2 envelope in Lv2-mediated restriction. Virology 2005; 332: 347-358.
34. Marchant D, Neil SJ, Aubin K, et al. An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. J Virol 2005; 79: 9410-9418.
35. Wilkes FJ, Rohll JB, Radcliffe PA, et al. 2006; manuscript in preparation.
36. Yee JK, Friedmann T, Bums JC. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 1994; 43(Pt A): 99-112.
37. Azzouz M, Ralph S, Wong LF, et al. Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector. Neuroreport 2004; 15: 985-990.
38. Rohll JB, Mitrophanous KA, Martin-Rendon E, et al. Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol 2002; 346: 466-500.
39. Martin-Rendon E, White LJ, Olsen A, et al. New methods to titrate EIAV-based lentiviral vectors. Mol Ther 2002; 5: 566-570.
40. Miskin J, Kingsman SM, Mitrophanous K. Assays for the quality control of lentiviral vectors. In Vol. Dropulic B, Carter BJ (eds). Wfley[Imprint], Inc: submitted.
41. Miskin J, Chipchase D, Rohll J, et al. A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors. Gene Ther 2006; 13: 196-205.
42. Sastry L, Johnson T, Hobson MJ, et al. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther 2002; 9: 1155-1162.
43. Kim VN, Mitrophanous; K, Kingsman SM, et al. Minimal requirement for a Ientivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72: 811-816.
44. Azzouz M, Martin-Rendon E, Barber RD, et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 2002; 22: 10302-10312.
45. Jarraya B, Ralph GS, Shin M, et al. 2007; manuscript in preparation.
46. Kotsopoulou. E, Kim VN, Kingsman AJ, et al. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 2000; 74: 4839-4952.
47. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
48. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979; 76: 4350-4354.
49. Lefrancois L, Lyles DS. The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. II. Monoclonal antibodies of nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes. Virology 1982; 121: 168-174.
50. Towers GJ, Hatziioannou T, Cowan S, et al. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003; 9: 1138-1143.
51. Qiu Z, Hobman TC, McDonald HL, et al. Role of N-linked oligosaccharides in processing and intracellular transport of E2 glycoprotein of rubella virus. J Virol 1992; 66: 3514-3521.
52. Li Z, Pinter A, Kayman SC. The critical N-linked glycan of murine leukemia virus envelope protein promotes both folding of the C-terminal domains of the precursor polyprotein and stability of the postcleavage envelope complex. J Virol 1997; 71: 7012-7019.
53. Roberts PC, Garten W, Klenk HD. Role of conserved glycosylation sites in maturation and transport of influenza A virus hemagglutinin. J Virol 1993; 67: 3048-3060.
54. Beyene A, Basu A, Meyer K, et al. influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity. Virology 2004; 324: 273-285.
55. Delos SE, Burdick MJ, White JM. A single glycosylation site within the receptor-binding domain of the avian sarcoma/leukosis virus glycoprotein is critical for receptor binding. Virology 2002; 294: 354-363.
56. von Messling V, Cattaneo R. N-linked glycans with similar location in the fusion protein head modulate paramyxovirus fusion. J Virol 2003; 77: 10202-10212.
57. Fournillier A, Wychowski C, Boucreux D, et al. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol 2001; 75: 12088-12097.
58. Cole KS, Steckbeck JD, Rowles JL, et al. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J Virol 2004; 78: 1525-1539.
59. Hanna SL, Pierson TC, Sanchez MD, et al. N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. J Virol 2005; 79: 13262-13274.
60. Cannon KS, Hebert DN, Helenius A. Glycan-dependent and - independent association of vesicular stomatitis virus G protein with calnexin. J Biol Chem 1996; 271: 14280-14284.
61. Maggioni C, Braakman I. Synthesis and quality control of viral membrane proteins. Curr Topics Microbiol Immunol 2005; 285: 175-198.
62. Marriott AC. Complete genome sequences of Chandipura and Isfahan vesiculoviruses. Arch Virol 2005; 150: 671-680.
63. Peisajovich SG, Shai Y. Viral fusion proteins: multiple regions contribute to membrane fusion. Biochim Biophys Acta 2003; 1614: 122-129.
64. Zhu P, Liu J, Bess J Jr, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006; 441: 847-852.
65. Mastromarino P, Conti C, Goldoni P, et al. Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J Gen Virol 1987; 68: 2359-2369.
66. Conti C, Mastromarino P, Riccioli A, et al. Electrostatic interactions in the early events of VSV infection. Res Virol 1991; 142: 17-24.
67. Guibinga GH, Miyanohara A, Esko JD, et al. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther 2002; 5: 538-546.
68. Cameiro FA, Lapido-Loureiro PA, Cordo SM, et al. Probing the interaction between vesicular stomatitis virus and phosphatidylserine. Eur Biophys J 2005; 1-10.
69. Blumenthal R. Cooperativity in viral fusion. Cell Biophys 1988; 12: 1-12.
70. Puri A, Winick J, Lowy RJ, et al. Activation of vesicular stomatitis virus fusion with cells by pretreatment at low pH. J Biol Chem 1988; 263: 4749-4753.
71. Nagata S, Kurata T, Ueno Y, et al. Vesicular stomatitis virus-mediated cell fusion subsequent to virus adsorption at different pH values. Jpn J Med Sci Biol 1991; 44: 171-180.
72. Yang X, Kurteva S, Ren X, et al. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 2005; 79: 12132-12147.
73. Andreadis S, Lavery T, Davis HE, et al. Toward a more accurate quantitation of the activity of recombinant retroviruses: alternatives to titer and multiplicity of infection. J Virol 2000; 74: 1258-1266.